New Chemical Entity (NCE)

Not to be confused with No-Cost Extension, the grants-management term also abbreviated NCE — see CASRAI’s No-cost extension (NCE) entry if that is what you were looking for.

A New Chemical Entity (NCE) is FDA’s classification for a small-molecule drug substance whose active moiety — the specific chemical structure responsible for its therapeutic action — has not been previously approved by FDA in any application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act. NCE is the small-molecule subset of the broader New Molecular Entity (NME) classification, and the specific subset that qualifies for a distinct five-year regulatory exclusivity period under 21 CFR 314.108 — the practical reason the NCE/NME distinction is worth knowing rather than treating the two acronyms as interchangeable.

NCE vs. NME: why the narrower category exists

Every NCE is an NME, but not every NME is an NCE. NME is the umbrella classification covering any drug — small-molecule or biologic — with no previously approved active moiety. NCE narrows that to the small-molecule chemical drugs specifically, because that narrower group is what 21 CFR 314.108 grants a specific, statutorily defined exclusivity period to. A novel biologic is an NME (sometimes called a New Biological Entity, or NBE, in FDA’s own reporting) but is not an NCE, and its post-approval exclusivity runs under the Public Health Service Act’s separate biologics framework rather than 314.108.

The five-year exclusivity mechanism

Under 21 CFR 314.108(a), an NCE is a drug containing no active moiety previously approved in any application submitted under FDCA section 505(b). A drug meeting that definition can receive five years of marketing exclusivity on approval, during which FDA is generally barred from accepting an Abbreviated New Drug Application (ANDA) or a 505(b)(2) application that relies on the same active moiety — the mechanism that keeps generic competitors out of the market for that period regardless of whether the sponsor also holds patent protection. This exclusivity is a creature of the Hatch-Waxman framework (the Drug Price Competition and Patent Term Restoration Act of 1984) and runs on its own statutory clock, independent of, and sometimes longer or shorter than, whatever patents the sponsor separately holds on the compound.

FDA’s interpretation of this rule has evolved for fixed-dose combination products specifically: historically, a combination containing even one previously approved active moiety was ineligible for the full five-year exclusivity, even if it also contained a genuinely new one. FDA revised that interpretation in 2014 guidance to better incentivize combination-product development, recognizing that fixed-dose combinations had become increasingly common in several therapeutic areas.

What does not qualify

Three cases commonly get miscategorized as NCEs and are worth naming explicitly:

• A new salt, ester, or formulation of an already-approved active moiety — the active moiety itself is not new, so this is not an NCE, even if the resulting product requires its own clinical studies and earns narrower three-year exclusivity.
• A novel biologic — this is an NME (and an NBE), but not an NCE; biologics are reviewed under the Public Health Service Act, not the 505(b) framework 314.108 references.
• A new fixed-dose combination built from two already-approved active moieties — combining existing ingredients, without a genuinely new active moiety in the mix, does not create an NCE regardless of how novel the combination itself is.

Worked example

A sponsor synthesizes a novel small-molecule compound and files an NDA. No active moiety in the compound has ever appeared in a previous FDA application under section 505(b). FDA classifies the application as both an NME and an NCE; on approval, the drug receives five years of exclusivity under 314.108, during which no ANDA or 505(b)(2) application relying on that active moiety can be accepted.

Counter-example

A sponsor files an NDA for a fixed-dose combination pairing a previously approved active moiety with a genuinely novel one. Under FDA’s pre-2014 interpretation this combination would not have qualified for five-year NCE exclusivity at all, because it contained a previously approved moiety; under the revised 2014 interpretation, it may still be eligible, reflecting FDA’s updated approach to combination products specifically.

Related CASRAI content

See New Molecular Entity (NME) for the broader classification NCE sits inside, 21 CFR Part 314 for the NDA framework and Subpart D exclusivity determinations generally, and No-cost extension (NCE) if you arrived here looking for the grants-management meaning of the same acronym.

Frequently Asked Questions

What’s the difference between NCE and NME?

NME (New Molecular Entity) is the broader classification for any drug — small-molecule or biologic — whose active moiety has not been previously approved by FDA. NCE (New Chemical Entity) is the small-molecule subset of NME specifically, and the subset that 21 CFR 314.108 grants five-year exclusivity to. Every NCE is an NME; not every NME is an NCE.

Does five-year NCE exclusivity replace patent protection?

No. NCE exclusivity under 21 CFR 314.108 runs on its own statutory clock, independent of any patents the sponsor holds on the compound. A sponsor can have patent protection that extends well beyond the five-year exclusivity window, or exclusivity that outlasts a weak or successfully challenged patent — the two protections are separate and can end at different times.